title: Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b.
abstract: The Ets transcription factor PU.1 is a hematopoietic master regulator essential for the development of myeloid and B-cell lineages. As we previously reported, PU.1 sometimes represses transcription on forming a complex with mSin3A-histone deacetyl transferase-MeCP2. Here, we show an interaction between PU.1 and DNA methyltransferases, DNA methyltransferase (Dnmt)3a and Dnmt3b (Dnmt3s). Glutathione-S-transferase pulldown assay revealed that PU.1 directly interacted with the ATRX domain of Dnmt3s through the ETS domain. Dnmt3s repressed the transcriptional activity of PU.1 on a reporter construct with trimerized PU.1-binding sites. The repression was recovered by addition of 5-aza-deoxycitidine, a DNA methyltransferase inhibitor, but not trichostatin A, a histone deacetylase inhibitor. Bisulfite sequence analysis revealed that several CpG sites in the promoter region neighboring the PU.1-binding sites were methylated when Dnmt3s were coexpressed with PU.1. We also showed that the CpG sites in the p16(INK4A) promoter were methylated by overexpression of PU.1 in NIH3T3 cells, accompanied by a downregulation of p16(INK4A) gene expression. These results suggest that PU.1 may downregulate its target genes through an epigenetic modification such as DNA methylation.
authors.affiliation: Department of Cell Genetics, Sasaki Institute, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Suzuki
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: F
authors.initials: F
authors.lastname: Kihara-Negishi
authors.forename: T
authors.initials: T
authors.lastname: Sakurai
authors.forename: E
authors.initials: E
authors.lastname: Hara
authors.forename: D G
authors.initials: DG
authors.lastname: Tenen
authors.forename: N
authors.initials: N
authors.lastname: Hozumi
authors.forename: T
authors.initials: T
authors.lastname: Oikawa
mesh_terms: D000818:Animals; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D047369:Chromatin Immunoprecipitation; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000378:metabolism; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000235:genetics / Q000378:metabolism*; D019175:DNA Methylation; D000090205:DNA Methyltransferase 3A; D000077209:Decitabine; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism; D006877:Hydroxamic Acids / Q000494:pharmacology; D047468:Immunoprecipitation; D051379:Mice; D041681:NIH 3T3 Cells; D011401:Promoter Regions, Genetic; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000494:pharmacology*; D015534:Trans-Activators / Q000235:genetics / Q000494:pharmacology*; D014158:Transcription, Genetic; D000097584:DNA Methyltransferase 3B; D000099232:Proto-Oncogene Protein Spi-1
chemical_list: D001374:Azacitidine; D019941:Cyclin-Dependent Kinase Inhibitor p16; D004248:DNA (Cytosine-5-)-Methyltransferases; D000090205:DNA Methyltransferase 3A; D000077209:Decitabine; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases; D006877:Hydroxamic Acids; D011518:Proto-Oncogene Proteins; D015534:Trans-Activators; D000097584:DNA Methyltransferase 3B; D000099232:Proto-Oncogene Protein Spi-1; C000715535:Dnmt3a protein, mouse; C012589:trichostatin A